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50Sequential Bilateral Corneal Transplantation and
Graft SurvivalBERNHARD STEGER, ELINOR CURNOW, ROBERT CHEESEMAN, VITO ROMANO, ABIGAIL KAYE,
MARK JONES, AND STEPHEN KAYE, ON BEHALF OF THE NATIONAL HEALTH SERVICE BLOOD AND
TRANSPLANT OCULAR TISSUE ADVISORY GROUP AND CONTRIBUTING OPHTHALMOLOGISTS (OTAG
AUDIT STUDY 21) PURPOSE: To investigate graft survival and rejection
following sequential bilateral corneal transplantation.
 DESIGN: Retrospective cohort study.
 METHODS: The study included patients with Fuchs
endothelial dystrophy (FED), pseudophakic bullous kerat-
opathy (PBK), or keratoconus who had undergone a pene-
trating keratoplasty (PK), endothelial keratoplasty (EK),
or deep anterior lamellar keratoplasty (DALK) between
1999 and 2012. The main cohort included patients who
had received a first transplant in both eyes for the same
indication and a control cohort patients who had under-
gone a unilateral first corneal transplant. Main outcome
measures were graft rejection or failure at 5 years.
 RESULTS: A total of 11 822 patients were included, of
whom 9335 had a unilateral and 2487 bilateral corneal
transplantation. For patients with FED (P< .005) and
KC (P [ .03) but not PBK (P [ .19), a transplant in
the second eye was associated with a 50% reduction in
risk of graft failure within 5 years in the first eye (FED:
hazard ratio [HR] 0.47, 95% confidence interval [CI]:
0.34–0.64; KC: HR 0.50, 95% CI: 0.24–1.02). For
FED this was dependent on the type of transplant (EK:
HR 0.30, 95% CI: 0.17–0.52; PK: HR 0.61, 95% CI:
0.42–0.88). We found no association between a trans-
plant in the second eye and a rejection episode in the first
eye (KC P[ .19, FED P[ .39, PBK P[ .19).
 CONCLUSION: For FED and KC, a transplant in the
second eye was associated with a reduced risk of graft fail-
ure in the first eye, independent of inter-transplant time.
For FED this effect was pronounced following an EK in
the first eye, where the risk of failure was reduced by
70%. (Am J Ophthalmol 2016;170:50–57.  2016
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ORNEAL AND KIDNEY TRANSPLANTATION ARE THE
most commonly performed types of transplanta-
tion.1 The cornea differs from other tissues or or-
gans in that it is a privileged site for transplantation
owing to the absence of blood and lymphatic vessels, rela-
tive paucity of mature antigen-presenting cells, blood-eye
barrier, and immunomodulatory factors within the eye.2
Despite this, corneal graft failure is significant, with an
overall 5-year graft survival of 71% (95% confidence inter-
val [CI]: 69%–73%).3 Corneal transplants fail pre-
dominantly from endothelial failure, as these cells do
not divide and depend on survival of the donor endothe-
lium. Corneal graft rejection and/or inflammation in the
recipient are significant causes of endothelial failure.4,5
Many of the risk factors associated with rejection are
well recognized, including young recipient age,
vascularization, sex mismatch, and previous rejection
episodes.6,7 In addition to donor- and recipient-related
risk factors, graft survival is also dependent on the indica-
tion—for example, Fuchs endothelial dystrophy (FED),
pseudophakic bullous keratopathy (PBK), and keratoconus
(KC)—and the type of transplant—for example, pene-
trating keratoplasty (PK), endothelial keratoplasty (EK;
Descemet-stripping endothelial keratoplasty [DSAEK] or
Descemet membrane endothelial keratoplasty [DMEK]),
or deep anterior lamellar keratoplasty (DALK).8–12
Although there is a significant increase in the rate of
rejection in an eye receiving a second corneal transplant,13
the effect of a transplant in the fellow or second eye on graft
survival in either eye is unclear. This is an important ques-
tion, because the common indications for corneal trans-
plantation involve both eyes. Previous investigations
have yielded conflicting results on the graft survival
and rejection in patients undergoing bilateral corneal
transplantation.13–16 The UK Transplant Registry offers
an opportunity to address these issues, particularly as
completion of transplant outcome data are a requirement
for all transplants registered with National Healthy
Service (NHS) Blood and Transplant. In order to
investigate whether a transplant in the fellow eye was
associated with graft survival and rejection in the first
eye, graft failure and rejection in patients who have had
sequential bilateral and unilateral corneal transplants
were compared, taking into account the indication and
type of transplant.0002-9394/$36.00
http://dx.doi.org/10.1016/j.ajo.2016.07.019
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FIGURE 1. Schematic of graft survival in the first eye, illus-
trating a time-dependent Cox regression model. Estimated base-
line survivor function before and following transplant in the
second (fellow) eye shown. Recipients start on the baseline sur-
vivor curve (solid line). If a recipient never receives a transplant
in their second eye, they remain on the bottom curve. At the
time of the transplant in the second eye, the recipient ‘‘jumps’’
to the top curve, representing graft survival for the bilateral
group. The vertical dotted line represents the median time to
the transplant in the second eye, that is, the median time
when the ‘‘jump’’ would occur. At the time of each graft failure
in the cohort, the risk set includes only those patients who have
survived to that time. This allows a direct comparison of patients
with identical survival who had or had not received a second eye
graft at that time. If the second eye graft for a particular recip-
ient occurred after 1 such event, that recipient would be
included in the ‘‘no second eye graft’’ category until the time
of their second eye graft. The hazard ratio associated with the
second eye graft is then interpreted as the hazard of graft failure
for a recipient who received a second eye graft compared with
one who did not, where the 2 recipients have the same values
of all other covariates at that time.18METHODS
IN A RETROSPECTIVE COHORT STUDY, DATA FROM THE UK
Transplant Registry were provided by and analyzed in
collaboration with NHS Blood and Transplant, which
provided institutional board approval. In the UK Trans-
plant Registry, blanket informed consent is obtained at
the time of corneal transplantation from all patients,
allowing the use of registry data for scientific purposes.
The study cohort comprised patients over 18 years in
the UK with FED, PBK, and KC (which are the main
indications for corneal transplantation11,17) who had
undergone either a PK, EK, or DALK between April 1,
1999 and March 31, 2012. The bilateral cohort
included all patients who had received a first transplant
in both eyes, where the indication was the same in both
eyes and the transplant in the second eye occurred
within the follow-up period for the transplant in the first
eye (maximum of 5 years) and before graft failure in the
first eye. A control cohort included all patients who un-
derwent unilateral first corneal transplant for the same
indication during the same period. Patients who under-
went a transplant in the second eye beyond the follow-
up period for the first eye or after graft failure in the first
eye were also included in the control cohort. Patient and
outcome data were collected at the time of the transplant
and then at 1 year, 2 years, and 5 years post-transplant.
All data were obtained from the UK Transplant Registry
for corneas supplied through the UK corneal transplant
service (CTS) eye banks.
 POST-TRANSPLANT ENDPOINTS: For the bilateral
cohort, survival of the graft in either the first or second
eye within 3 years of the time of transplant in the second
eye was analyzed. In analyses comparing the bilateral and
control cohorts, survival and time to rejection of the first
eye graft within 5 years of the time of transplant in the first
eye were the endpoints of interest. Survival times were
censored for patients with a functioning graft at last
follow-up. Time to rejection was censored for patients
without rejection at last follow-up.
 ANALYSIS: Recipient and transplant characteristics of
the bilateral cohort were summarized as counts and per-
centages. For the bilateral cohort, the median time be-
tween transplants in the first and second eye was defined
as the inter-transplant time (ITT) and compared across in-
dications using the Kruskal-Wallis test. Kaplan-Meier esti-
mates of first and second eye graft survival from time of
second eye graft were compared across ITT categories
(<1 year, 1–2 years, >2 years) for each indication using
the log-rank test. The association between ITT and first
and second eye graft survival from time of second eye graft
was further investigated using Cox regression. Nonlinear
associations between ITT and first and second eye graft sur-
vival were assessed using the likelihood ratio test,VOL. 170 GRAFT SURVIVAL IN BILAcomparing a linear form of ITT with the categorical form
of ITT. In analyses comparing the bilateral cohort and
the control cohort, survival and rejection-free rates for
the first eye graft at 5 years post-transplant were estimated
using the Kaplan-Meier method. The association between
receiving a graft in the second eye and survival and rejec-
tion of the first eye graft was investigated using Cox regres-
sion. Because it was not known if and when a recipient
would receive a transplant in the fellow eye at the time
of the transplant in the first eye, a time-dependent indica-
tor variable that changed from 0 to 1 at the time of the
transplant in the second eye was used in the model, as
shown in Figure 1. Regression analyses were performed
separately for patients with FED, PBK, and KC, adjusting
for the type of transplant (PK, DALK, and EK) as appro-
priate to that indication, low- or high-risk recipient51TERAL KERATOPLASTY
TABLE 1. Recipient and Transplant Characteristics of the
Bilateral Cohort at the Time of the First Graft
Characteristic Level N (%)
Graft type PK 1093 (69)
DALK 134 (8)
EK 357 (23)
Indication KC 504 (32)
FED 991 (63)
PBK 89 (6)
Recipient sex Male 748 (47)
Female 836 (53)
Recipient age (y) 19–40 439 (28)
41–60 220 (14)
61–75 587 (37)
>75 338 (21)
HLA-matched No 1546 (98)
Yes 38 (2)
High-risk No 1123 (71)
Yes 461 (29)
Other intraocular surgeries at time of graft No 1071 (68)
Yes 513 (32)
Complications at time of graft No 1564 (99)
Yes 20 (1)
Postoperative surgery prior to graft failure No 1440 (91)
Yes 144 (9)
Postoperative surgery prior to rejection No 1451 (92)
Yes 133 (8)
Time between first eye and second eye graft
(y)
<1 322 (20)
1–2 587 (37)
>2 675 (43)
DALK ¼ deep anterior lamellar keratoplasty; EK ¼ endothelial
keratoplasty; FED¼ Fuchs endothelial dystrophy; HLA ¼ human
leukocyte antigen; KC ¼ keratoconus; PBK ¼ pseudophakic
bullous keratopathy; PK ¼ penetrating keratoplasty.
Bilateral cohort defined as patients who underwent a trans-
plant in the second eye within the follow-up period (maximum
of 5 years) of the transplant in the first eye graft and prior to graft
failure in the first eye graft.(high risk defined as any ocular surface disease, corneal
vascularization, or glaucoma at time of transplant), and,
for KC and FED patients, postoperative intraocular surgery
(predominantly cataract surgery) in either eye following
the transplant prior to graft failure and/or rejection. Postop-
erative intraocular surgery was included as a time-
dependent variable. Analyses were undertaken using
SAS/STAT version 9.4 (SAS Institute Inc, Cary, North
Carolina, USA).RESULTS
ATOTALOF 11 822 PATIENTSWERE INCLUDED,OFWHOM2487
had undergone bilateral corneal transplantation within the
study period. Of the 2487 patients with bilateral corneal52 AMERICAN JOURNAL OFtransplants, 1584 (64%) had undergone transplants in
both eyes within the follow-up period for the first eye and
before graft failure in the first eye; 743 patients (30%)
had a functioning graft in the first eye at last follow-up
but received a transplant in the second eye beyond the
known follow-up period for the first eye; 114 patients
(5%) received a transplant in the second eye after having
had a repeat transplant in the first eye; and 46 patients
(2%) received a transplant in the second eye after graft fail-
ure in the first eye, but before or without a repeat transplant
in the first eye. Therefore, 1584 patients were defined as
bilateral recipients for the purpose of this study. Of these,
the proportions receiving the same type of transplant in
the second eye as in the first eye were as follows: EK,
98%, PK, 80%, and DALK, 78%. Follow-up data for the
transplant in the second eye were missing for 59 patients
(3.7%). For these recipients, only data for the transplant
in the first eye were used. Recipient and transplant charac-
teristics for the bilateral cohort are shown in Table 1.
Median ITT was higher for patients with KC (median
734 days, interquartile range [IQR] 503–1110 days) than
for those with FED (median 616 days, IQR 378–
981 days) and lowest for PBK (median 535 days, IQR
322–823 days) (P < .0005). We found no evidence of a
nonlinear association between ITT and first and second
eye graft survival for any indication (P > .2 in all cases)
and hence a continuous linear form of ITT was used in
all regression models. Graft survival in the first eye at 3
years from transplant in the second eye was higher for pa-
tients with KC (97.9%, 95% CI: 95.6%–99.0%) than for
those with FED (92.4%, 95% CI: 89.5%–94.5%) and
lowest for patients with PBK (74.7%, 95% CI: 60.1%–
84.7%) (P < .0005). Importantly, however, within each
indication first eye graft survival estimates were similar,
regardless of ITT (KC P ¼ .16, FED P ¼ .25, PBK P ¼
.17) (Figure 2). After risk adjustment, we found no associ-
ation between ITT and graft survival in the first eye (KC
P ¼ .14, FED P ¼ .59, PBK P ¼ .97) (Table 2). Similar
to the first eye, graft survival in the second eye at 3 years
from transplant in the second eye was higher for patients
with KC (94.6%, 95% CI: 91.8%–96.4%) than for those
with FED (88.5%, 95% CI: 86.0%–90.6%) and lowest for
those patients with PBK (75.3%, 95% CI: 61.4%–84.8%)
(P < .0005). Again, within each indication, estimates of
graft survival in the second eye graft were similar, regardless
of ITT (KC P¼ .80, FED P¼ .74, PBK P¼ .36). After risk
adjustment, we found no association between ITT and graft
survival in the second eye (KC P ¼ .92, FED P ¼ .07, PBK
P ¼ .38) (Table 2).
For all 11 822 patients who received a first eye graft, the
overall 5-year graft survival rates were 91% (95%CI: 90%–
92%) for KC, 78% (95% CI: 76%–80%) for FED, and 53%
(95% CI: 51%–56%) for PBK. The overall 5-year
rejection-free rates were 83% (95% CI: 81%–84%) for
KC, 87% (95% CI: 85%–88%) for FED, and 77% (95%
CI: 75%–79%) for PBK. Analysis of first eye graft outcomesOCTOBER 2016OPHTHALMOLOGY
FIGURE 2. First eye graft survival, from the time of transplant in the second eye, by inter-transplant time (ITT) and indication for
the bilateral cohort. Within each indication, graft survival in the first eye was similar for all categories of ITT (keratoconus [KC]
P[ .16, Fuchs endothelial dystrophy [FED] P[ .25, pseudophakic bullous keratopathy [PBK] P[ .17).
TABLE 2. Inter Transplant Time
Parameter
Transplants
(N)
Graft Failure
(N)
Hazard Ratio (95% CI) for
Each Year Increase in ITT P Value
Risk of graft failure in the first eye
KCa 504 7 0.50 (0.19–1.31) .14
FEDa 991 40 1.11 (0.76–1.64) .59
PBKb 89 15 0.99 (0.50–1.96) .97
Risk of graft failure in the second eye
KCa 489 22 1.02 (0.70–1.47) .92
FEDa 950 91 1.18 (0.99–1.40) .07
PBKb 86 15 1.22 (0.79–1.87) .38
CI ¼ confidence interval; FED ¼ Fuchs endothelial dystrophy;
KC ¼ keratoconus; PBK ¼ pseudophakic bullous keratopathy.
Association between inter-transplant time and risk of graft fail-
ure in the first and second eyes within 3 years of transplant in the
second eye described using Cox regression analysis. Separate
models were created for each indication (KC, FED, or PBK).
aAdjusted for graft type, low or high risk, and postoperative
surgery prior to failure.
bAdjusted for graft type and low or high risk.for the whole study cohort indicated that, for patients with
FED and KC, the risk of graft failure within 5 years in the
first eye for patients who received a transplant in the second
eye was half that of patients who did not receive a trans-
plant in the second eye (FED: hazard ratio [HR] 0.47,
95% CI: 0.34–0.64, P < .005; KC: HR 0.50, 95% CI:
0.24–1.02, P ¼ .03) (Table 3). By including an interaction
term in each model (type of transplant in the first eye
by second eye graft), we found that this effect wasVOL. 170 GRAFT SURVIVAL IN BILAindependent of the type of transplant in the first eye for
KC (P ¼ .23) but not for FED (P ¼ .03, EK: HR 0.30,
95% CI: 0.17–0.52; PK: HR 0.61, 95% CI: 0.42–0.88).
For patients with PBK we found no association between a
transplant in the second eye and graft failure in the first
eye, regardless of the type of transplant in the first eye
(HR 0.69, 95% CI:0.42–1.14, P ¼ .61). As an additional
measure of how well the first eye graft was doing post-
transplant, we also included post-transplant corrected
logMAR visual acuity in the first eye as a time-varying co-
variate in each model. We still found that a transplant in
the second eye was associated with a reduced risk of graft
failure, although the confidence intervals are far wider
owing to missing values of logMAR visual acuity (FED:
HR 0.69, 95% CI: 0.45–1.04; KC: HR 0.49, 95% CI:
0.20–1.18; PBK: HR 0.76, 95%CI: 0.34–1.71). In addition,
we found no association between a transplant in the second
eye and the development of a rejection episode in the first
eye, regardless of the type of transplant in the first eye (KC
P¼ .48, FED P ¼ .11, PBK P ¼ .85) (Table 3). There were
only a few cases of graft failure or rejection within 5 years of
transplant where the type of transplant in the second eye
was different from that for the first eye (KC: graft failure,
2 cases, graft rejection, 13 cases; FED: graft failure, 6 cases,
graft rejection, 9 cases; PBK: graft failure, 1 case, graft rejec-
tion, 0 cases), so we were not able to estimate the effect of
type of transplant in the second eye.DISCUSSION
THE SUCCESS RATE OF CORNEAL TRANSPLANTATION IS
affected by the indication and type of transplant,17,19,2053TERAL KERATOPLASTY
TABLE 3. Graft Failure and Rejection
Parameter Level (Baseline) Transplants (N) Events (N)
Hazard Ratio (95% CI) for Graft in the Second Eye
Compared With No Graft P Value
Risk of graft failure in the first eye
KC: Graft in second eyea No 4104 285 1.00 (–)
Yes 504 7 0.50 (0.24–1.02) .03
FED: Graft in second eyea No 2966 540 1.00 (–)
Yes 991 47 0.47 (0.34–0.64) <.01
PBK: Graft in second eyeb No 3168 984 1.00 (–)
Yes 89 15 0.69 (0.42–1.14) .13
Risk of rejection in the first eye
KC: Graft in second eyea No 4104 546 1.00 (–)
Yes 504 58 0.72 (0.43–1.20) .19
FED: Graft in second eyea No 2966 277 1.00 (–)
Yes 991 78 0.85 (0.59–1.23) .39
PBK: Graft in second eyeb No 3168 466 1.00 (–)
Yes 89 11 0.55 (0.20–1.47) .19
CI ¼ confidence interval; FED ¼ Fuchs endothelial dystrophy; KC ¼ keratoconus; PBK ¼ pseudophakic bullous keratopathy.
Association between graft in the second eye and risk of graft failure or rejection in the first eye within 5 years of transplant in the first eye
described using Cox regression analysis. Separate models were created for each indication (KC, FED, or PBK). Includes bilateral and control
cohorts.
aAdjusted for graft type, low or high risk, and postoperative surgery prior to failure.
bAdjusted for graft type and low or high risk.complications at the time of surgery,21 and both
donor17,22,23 and recipient factors such as age, ocular
surface disease, corneal neovascularization, and
glaucoma.22,24–26 The role of matching for human
leukocyte antigen on graft rejection and survival is
unclear.27–29 Two of the main indications for corneal
transplantation, FED and KC,11,17 are bilateral conditions
and, as such, many of these patients may undergo
transplantation in both eyes. The effect of laterality and
time order of bilateral corneal transplantation, however,
has yielded conflicting results,15,16,30,31 possibly owing to
small single-center studies15,30,31 or reliance on voluntary
reporting.16 In this study we used a large dataset from the
UK Transplant Registry, including first and second eye
grafts for 1584 recipients and first eye grafts for 10 238 re-
cipients. Provision of follow-up data is a requirement of
all surgeons undertaking corneal transplantation in the
UK. One of the inherent weaknesses in studies using regis-
try data is that the accuracy of the data will depend on the
completeness and quality of the information that is
collected. In the UK, the UK Transplant Registry was
established to collect data nationwide in a standardized
reporting format, which reduces errors owing to misclassifi-
cation and misreporting. Despite the inherent weakness in
this system there is a high return rate of 97% for the trans-
plant record and high return rates of 86%, 84%, and 80%
for the 1-, 2-, and 5-year follow-up forms, respectively
(Jones MNA. Summary of form return rates—OTAG 15.
NHS Blood and Transplant 29th Meeting of The Ocular54 AMERICAN JOURNAL OFTissue Advisory Group. January 2016). In particular, for
the bilateral cohort, there was a very high data return
rate, with only 3.7% of follow-up data missing for the trans-
plant in the second eye.
For all the included cases, the overall Kaplan-Meier esti-
mates of graft failure and graft rejection in the first eye
within 5 years was 24% and 17%, respectively, which is
similar to previous reports.19,20 The overall chance of
corneal graft rejection was reduced after EK compared
with PK in patients with a diagnosis of FED or PBK.
Likewise, the chance of graft rejection was lower after
DALK compared with PK in patients with a diagnosis of
KC. Both of these findings are in concordance with
literature.4,9,32 In terms of other reported and known risk
factors, the results of this and other studies confirm that
the risks of corneal graft rejection and/or failure are
associated with the indication and type of corneal
transplant, presence of recipient risk factors such as age
and inflammation, and intraoperative
complications.21,25,26 For patients who had undergone a
corneal transplant in both eyes, however, for both FED
and KC, the risk of graft failure in the eye that received
the first transplant was reduced by 50% when the
transplant in the second eye was carried out before failure
of the transplant in the first eye. Importantly for patients
with FED this association differed for each type of
transplant in the first eye (EK: HR 0.30, 95% CI: 0.17–
0.52; PK: HR 0.61, 95% CI: 0.42–0.88, P ¼ .03). That is,
the risk reduction was more pronounced if they hadOCTOBER 2016OPHTHALMOLOGY
undergone an EK in their first eye where the risk of failure
was reduced by 70%, compared with a 40% reduction in
risk if they had undergone a PK. Although the type of
transplant in the first eye was considered, no adjustment
was made for the type of transplant in the second eye
owing to the small number of cases of graft failure or
rejection where the type of transplant in the second eye
was different from that for the first eye. The type of
transplant, however, was usually the same for both eyes.
The different associations with graft survival between
EK and PK may be related to the severing of corneal nerves
in PK and the role of substance p secretion.33 In a recent
report of a mouse model studying the role of bilateral sub-
stance p secretion, it was noted that severing of corneal
nerves in the process of unilateral recipient bed preparation
abolished the corneal immune privilege in the opposite eye
through a reduction in substance p.33
In contrast to FED and KC, we found no significant asso-
ciation between a transplant in the second eye and graft
failure in the first eye for PBK patients. The absence of
an association in patients with PBK may be explained by
the generally poor graft survival for PBK.34,35 For all 3
indications, however, we found no association between
inter-transplant time and graft survival in either the first
eye or the second. This would suggest that for FED and
KC the improved survival of the graft in the first eye was
independent of the time between transplants (within the
5-year period studied).
In contrast to graft failure, we found no significant differ-
ence in the risk of rejection following a transplant in the
second eye compared with patients who did not receive a
transplant in the second eye. This needs to be viewed
with caution, as the definition and significance of a rejec-
tion episode would have been at the discretion of the
reporting transplant surgeon. As opposed to the reporting
of graft failure, low-grade inflammation and rejection may
not have been evident or the patient may not have
presented, so that episodes of rejection could have been
missed. Such cases of low-grade rejection, however, would
be expected to be at an increased risk of subsequent graft
failure. Musch and Meyer14 and Ozbek and associates15
found no increase in rejection episodes after a transplant
in the second eye, whereas Williams and associates16 and
Coster and Williams13 found that a rejection episode in 1
eye was associated with an increased risk of rejection in
the other eye. Tuft and associates31 reported that a trans-
plant in the contralateral eye was associated with an
increased risk of rejection in the first eye that received a
transplant. This conflicting evidence possibly reflects the
design and length of follow-up in these studies, particularly
as there is a higher risk of graft failure and rejection in the
early postoperative phase, which then decreases over
time.16,36 There have also been case reports in the
literature of bilateral corneal graft rejection occurring
within 6 weeks to 1 year of the transplant in the fellow
eye,5,14,30 that were thought to have been initiated by theVOL. 170 GRAFT SURVIVAL IN BILAtransplant in the second eye.14,16 It has been suggested
that this may be owing to systemic sensitization to
mismatched tissue histocompatibility antigens present in
1 graft, some of which are also present on the graft in the
contralateral eye.16 This is supported by the finding in a
rat model, where a second orthotopic corneal graft is
rejected at an accelerated rate compared to the first graft.37
Despite the eye being a relatively immune-privileged
site, it is not sequestered from the immune system. The
phenomenon of anterior chamber–associated immune de-
viation (ACAID) has been described, in which introduc-
tion of foreign antigen into the anterior chamber of the
eye results in suppression of the delayed-type hypersensitiv-
ity response to that antigen.2 Although speculative, in
sequential bilateral corneal transplantation, the first graft
would potentially benefit from 2 initiations of systemically
induced immune tolerance to human corneal tissue anti-
gen, which may have contributed to the increased survival
of the graft in the first eye in KC and FED. Steroid treat-
ment has been shown to be associated with improved graft
survival38 and is likely to be an important factor in the find-
ings of this study. Although the amount of steroid absorbed
following topical administration is small, it is possible that
the eye receiving the first transplant may have benefited
from systemic absorption of postoperative topical steroid
treatment to the second eye and thus receive additional
immunoprotection.39 Unfortunately, the duration and
type of topical corticosteroid treatment in this study was
not available to be included in the analysis. It may be hy-
pothesized that first eyes of patients undergoing a second
eye transplant remain on prolonged topical steroid treat-
ment and clinical follow-up. First eyes might therefore
benefit from earlier recognition and treatment of longer-
term graft complications, including loose sutures or mild
rejection episodes.
The present study may be subject to an inherent limita-
tion resulting from patients with failed first grafts being
more likely to receive a repeat transplant in the same
eye, whereas patients with surviving first grafts may be
more likely to receive a second eye transplant. In order to
address this healthy-eye bias, we adjusted for factors known
to be associated with graft outcome before quantifying the
effect of having a second eye graft. We used postoperative
intraocular surgery and visual acuity as measures of how
well the first eye graft was doing post-transplant. This infor-
mation, however, is only collected at 3 time points (at 1, 2,
and 5 years post-transplant) and visual acuity is poorly re-
ported at the point of graft failure. It is possible that we
have not been able to accurately identify patients doing
better in their first eye at the time of transplant in the sec-
ond eye, since there are large periods of time between each
point at which this information is captured. Reporting of
measures such as postoperative intraocular surgery and
visual acuity at more frequent intervals post-transplant
may improve assessment of whether patients not doing as
well in their first eye are less likely to have a graft in their55TERAL KERATOPLASTY
other eye. There may be other relevant factors that were
not considered and that influence graft survival, such as
type and duration of post-transplant steroid treatment.
Clearly, these issues could be addressed in a prospective
study.
There is little published to enable comparison to other
paired organs. In cases of renal re-transplantation, Lucarelli
and associates, although it was not the main purpose of
their paper, found better renal function at 2 years follow-
up and a reduced risk of acute graft rejection in patients
without preliminary nephrectomy of the failed kidney
transplant.40 In spite of very high data return rates to the
UK Transplant Registry, the proportion of first eye trans-
plants lost to follow-up was 20% after 5 years, and the study
may therefore be subject to a significant response-rate bias.
The main findings in this study are that for patients
with KC and FED, a transplant in the second eye was56 AMERICAN JOURNAL OFassociated with a 50% reduction in risk of graft failure
in the first eye irrespective of ITT, and that for patients
with FED the risk of failure was reduced by 70% if they
had undergone an EK compared to a reduction of 40% if
they had undergone a PK in their first eye. These results
may have important implications for clinical practice. It
is well established that repeat transplants in the same
eye have a much higher risk of graft failure.16 It is of
note, therefore, that of the bilateral transplant recipients,
only 2% received a transplant in the second eye after graft
failure in the first eye and before undergoing a repeat
transplant in the first eye. It is possible that patients
with FED (particularly if undergoing an EK) or those
with KC may benefit from a transplant in the second
eye, if clinically needed, before the first transplant has
failed, but a randomized study should be conducted to
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